Biomarker testing is an important part of precision medicine; however, many commercial health plans and state Medicaid programs lack adequate coverage, which can have life-threatening consequences for patients with cancer who could benefit from biomarker testing.

Some good news: health insurance coverage advocates have seen "wins" in three states in 2021: California, Illinois, and Louisiana. In this episode, we spoke with two healthcare advocates who explore these recent policy changes as it relates to biomarker testing. Tune in to find out what these legislative changes mean for your program or practice—and discover approaches to advise policymakers in your state on biomarker testing.

Guests:

Hilary Gee Goeckner, MSW

Senior State & Local Campaign Manager, Medicaid

American Cancer Society Cancer Action Network (ACS CAN)

Kristen Santiago, MS

Senior Director of Public Policy Initiatives

LUNGevity Foundation

Related Content:

• BiomarkerLIVE Project Overview
• [PODCAST] Ep 37: Financial Barriers to Biomarker Testing
• [VIDEO PODCAST] Ep 09: Precision Medicine Disparities
• [Abstract #123] Identifying barriers to equitable biomarker testing in underserved patients with NSCLC: A mixed-methods study to inform quality improvement opportunities
• [Abstract] A United States study focused on patients' understanding of, attitudes towards, and barriers to the use of biomarker testing for NSCLC
• Advanced NSCLC Biomarker Testing (CME/CMLE on-demand course)
• Current and Future Trends in NSCLC Biomarker Testing: The American Experience
• Biomarkers for Lung Cancer Screening and Detection
• Biomarker Testing for Patients with Advanced NSCLC: Real-World Issues and Tough Choices (ASCO Educational Book)
• Biomarkers in Lung Cancer (first page preview only)